drugset / Trial / NCT00964730
A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm
Phase 1
Completed
135 enrolled
Teva Branded Pharmaceutical Products R&D, Inc.
Cetero Research, San Antonio · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess whether multiple doses of Talampanel increase the QT interval when compared to placebo
Timeline
- Start
- 2009-10
- Primary completion
- 2010-01
- Completion
- 2010-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Moxifloxacin | Small molecule | — | — |
| Subject | Talampanel | Small molecule | 50 mg | — |
Indications
No indication recorded.